Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]F-AraG PET/CT Imaging in Alzheimer's Disease
NCT07611357Phase 2Not yet recruiting
- Sponsor
- CellSight Technologies
- Start
- May 2026
- Primary completion
- Sep 2029
01
Overview
Phase 2, open-label, single-arm trial of [18F]fluoro-arabinofuranosyl guanine in Alzheimer's disease (AD), sponsored by CellSight Technologies. Primary endpoints: [18F]F-AraG uptake in the brain, [18F]F-AraG uptake kinetics in the brain and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
[18F]fluoro-arabinofuranosyl guanine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07611357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07611357.